BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 38419499)

  • 21. Novel glycosylation zinc(II)-cryptolepine complexes perturb mitophagy pathways and trigger cancer cell apoptosis and autophagy in SK-OV-3/DDP cells.
    Zhou Z; Du LQ; Huang XM; Zhu LG; Wei QC; Qin QP; Bian H
    Eur J Med Chem; 2022 Dec; 243():114743. PubMed ID: 36116236
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ABT737 reverses cisplatin resistance by targeting glucose metabolism of human ovarian cancer cells.
    Xu Y; Gao W; Zhang Y; Wu S; Liu Y; Deng X; Xie L; Yang J; Yu H; Su J; Sun L
    Int J Oncol; 2018 Sep; 53(3):1055-1068. PubMed ID: 30015875
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exosomal miR-21-5p derived from cisplatin-resistant SKOV3 ovarian cancer cells promotes glycolysis and inhibits chemosensitivity of its progenitor SKOV3 cells by targeting PDHA1.
    Zhuang L; Zhang B; Liu X; Lin L; Wang L; Hong Z; Chen J
    Cell Biol Int; 2021 Oct; 45(10):2140-2149. PubMed ID: 34288231
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TAZ Regulates the Cisplatin Resistance of Epithelial Ovarian Cancer Cells via the ANGPTL4/SOX2 Axis.
    Li C; Wang Q; Luo Y; Xiang J
    Anal Cell Pathol (Amst); 2022; 2022():5632164. PubMed ID: 36247876
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lentivirus-Mediated RNAi silencing targeting ERCC1 reverses cisplatin resistance in cisplatin-resistant ovarian carcinoma cell line.
    Du P; Zhang X; Liu H; Chen L
    DNA Cell Biol; 2015 Jul; 34(7):497-502. PubMed ID: 25941922
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Propofol inhibits proliferation and cisplatin resistance in ovarian cancer cells through regulating the microRNA‑374a/forkhead box O1 signaling axis.
    Sun Y; Peng YB; Ye LL; Ma LX; Zou MY; Cheng ZG
    Mol Med Rep; 2020 Mar; 21(3):1471-1480. PubMed ID: 32016462
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Establishment and biological characteristics of a platinum-resistance nude mouse model in epithelial ovarian cancer].
    Shi L; Yu H; Zhang W; Li L; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):523-30. PubMed ID: 25327735
    [TBL] [Abstract][Full Text] [Related]  

  • 28. RCC2, a regulator of the RalA signaling pathway, is identified as a novel therapeutic target in cisplatin-resistant ovarian cancer.
    Gong S; Chen Y; Meng F; Zhang Y; Wu H; Li C; Zhang G
    FASEB J; 2019 Apr; 33(4):5350-5365. PubMed ID: 30768358
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Triptolide inhibits JAK2/STAT3 signaling and induces lethal autophagy through ROS generation in cisplatin‑resistant SKOV3/DDP ovarian cancer cells.
    Zhong Y; Le F; Cheng J; Luo C; Zhang X; Wu X; Xu F; Zuo Q; Tan B
    Oncol Rep; 2021 May; 45(5):. PubMed ID: 33760192
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long non-coding RNA Linc00312 modulates the sensitivity of ovarian cancer to cisplatin via the Bcl-2/Caspase-3 signaling pathway.
    Zhang C; Wang M; Shi C; Shi F; Pei C
    Biosci Trends; 2018 Jul; 12(3):309-316. PubMed ID: 29952351
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MicroRNA-1 overexpression increases chemosensitivity of non-small cell lung cancer cells by inhibiting autophagy related 3-mediated autophagy.
    Hua L; Zhu G; Wei J
    Cell Biol Int; 2018 Sep; 42(9):1240-1249. PubMed ID: 29851226
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tasquinimod enhances the sensitivity of ovarian cancer cells to cisplatin by regulating the Nur77-Bcl-2 apoptotic pathway.
    Lin Y; Liu YQ; Zhu KA; Hu MQ; Li Z; Min XJ
    Adv Clin Exp Med; 2024 Feb; 33(2):151-161. PubMed ID: 37501511
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Knockdown of MACC1 expression increases cisplatin sensitivity in cisplatin-resistant epithelial ovarian cancer cells.
    Zhang R; Shi H; Ren F; Li X; Zhang M; Feng W; Jia Y
    Oncol Rep; 2016 Apr; 35(4):2466-72. PubMed ID: 26794135
    [TBL] [Abstract][Full Text] [Related]  

  • 34. miR-29c-3p inhibits autophagy and cisplatin resistance in ovarian cancer by regulating FOXP1/ATG14 pathway.
    Hu Z; Cai M; Zhang Y; Tao L; Guo R
    Cell Cycle; 2020 Jan; 19(2):193-206. PubMed ID: 31885310
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Caseinolytic protease P (CLPP) activated by ONC201 inhibits proliferation and promotes apoptosis in human epithelial ovarian cancer cells by inducing mitochondrial dysfunction.
    Kou X; Ding H; Li L; Chao H
    Ann Transl Med; 2021 Sep; 9(18):1463. PubMed ID: 34734015
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Noscapine Increases the Sensitivity of Drug-Resistant Ovarian Cancer Cell Line SKOV3/DDP to Cisplatin by Regulating Cell Cycle and Activating Apoptotic Pathways.
    Shen W; Liang B; Yin J; Li X; Cheng J
    Cell Biochem Biophys; 2015 May; 72(1):203-13. PubMed ID: 25510462
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FGFR3 phosphorylates EGFR to promote cisplatin-resistance in ovarian cancer.
    Zhao J; Tan W; Zhang L; Liu J; Shangguan M; Chen J; Zhao B; Peng Y; Cui M; Zhao S
    Biochem Pharmacol; 2021 Aug; 190():114536. PubMed ID: 33794187
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Circ_0007841 knockdown confers cisplatin sensitivity to ovarian cancer cells by down-regulation of NFIB expression in a miR-532-5p-dependent manner.
    Gao Y; Huang Y
    J Chemother; 2023 Apr; 35(2):117-130. PubMed ID: 35380509
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Purvalanol A induces apoptosis and reverses cisplatin resistance in ovarian cancer.
    Zhang X; Hong S; Yang J; Liu J; Wang Y; Peng J; Wang H; Hong L
    Anticancer Drugs; 2023 Jan; 34(1):29-43. PubMed ID: 35946506
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Knockdown of long non-coding RNA HOTAIR reverses cisplatin resistance of ovarian cancer cells through inhibiting miR-138-5p-regulated EZH2 and SIRT1.
    Zhang Y; Ai H; Fan X; Chen S; Wang Y; Liu L
    Biol Res; 2020 Apr; 53(1):18. PubMed ID: 32349783
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.